Simvastatin Drug Combination Ezetimibe (Vytorin)

A pharmaceutical preparation of ezetimibe and simvastatin that is used in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS.

Also Known As:

Vytorin; Ezetimibe, Simvastatin Drug Combination; Ezetimibe Simvastatin Drug Combination; Ezetimibe-Simvastatin Combination; Ezetimibe-Simvastatin Drug Combination; Inegy; Combination, Ezetimibe-Simvastatin; Combination, Ezetimibe-Simvastatin Drug; Drug Combination, Ezetimibe-Simvastatin; Ezetimibe Simvastatin Combination

Networked: 67 relevant articles (38 outcomes, 44 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Cannon, Christopher P: 13 articles (10/2021 - 11/2008)
2.	Giugliano, Robert P: 13 articles (10/2021 - 11/2008)
3.	Braunwald, Eugene: 12 articles (10/2021 - 11/2008)
4.	Blazing, Michael A: 11 articles (10/2021 - 11/2008)
5.	Tershakovec, Andrew M: 10 articles (10/2021 - 02/2010)
6.	Park, Jeong-Gun: 8 articles (10/2021 - 01/2017)
7.	White, Jennifer A: 7 articles (01/2019 - 08/2014)
8.	Murphy, Sabina A: 5 articles (12/2018 - 02/2016)
9.	Wiviott, Stephen D: 4 articles (09/2020 - 01/2017)
10.	Bohula, Erin A: 4 articles (12/2018 - 02/2016)

Related Diseases

1.	Acute Coronary Syndrome 01/01/2019 - "We evaluated medication discontinuation in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), which evaluated placebo+simvastatin versus ezetimibe+simvastatin in patients hospitalized with the acute coronary syndrome and followed longitudinally postdischarge. " 09/01/2020 - "The purpose of this study was to clarify this unexpected finding in a larger sample size of patients stabilized after acute coronary syndrome, we conducted a prospective systematic analysis of malignancy events in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). " 01/01/2017 - "Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)." 11/01/2008 - "Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes." 10/01/2016 - "After an acute coronary syndrome, the 6-year results of the "IMPROVE-IT" randomized trial showed a 1.6% reduction in the number of nonfatal myocardial infarctions with the ezetimibe + simvastatin combination compared with simvastatin alone, but no reduction in mortality."
2.	Stroke (Strokes) 01/01/2016 - "To investigate the effect of ezetimibe-simvastatin combination therapy on stroke prevention among diabetic stroke patients. " 05/01/2016 - "Data from the recently published Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) now offer a clear proof of this concept, demonstrating that pure cholesterol lowering, as obtained with ezetimibe, plays an important role in reducing stroke. " 12/19/2017 - "We investigated the efficacy of the addition of ezetimibe to simvastatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), with a focus on patients with a stroke before randomization. " 01/01/2021 - "In this second part of the review of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), the findings in relation to patients with stroke, the ACS phenotype, history of coronary artery bypass graft surgery, heart failure, concurrent polyvascular atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus, and different levels of expression of selected cardiovascular biomarkers, are discussed. " 12/01/2018 - "Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)"."
3.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2007 - "This article will review clinical experience with ezetimibe/simvastatin combination, commenting upon its place and potential value in the prevention of cardiovascular disease." 05/01/2013 - "A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease." 03/01/2016 - "The review discusses some of the distinctions between the guidelines, including how to determine a patient's atherosclerotic cardiovascular disease risk, the role of lipoprotein treatment targets, the importance of moderate- and high-intensity statin therapy, and the use of nonstatin therapy in light of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) trial. " 05/01/2015 - "The review discusses some of the distinctions between the guidelines, including how to determine a patient's atherosclerotic cardiovascular disease risk, the role of lipoprotein treatment targets, the importance of moderate- and high-intensity statin therapy, and the use of nonstatin therapy in light of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) trial." 01/01/2021 - "In this second part of the review of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), the findings in relation to patients with stroke, the ACS phenotype, history of coronary artery bypass graft surgery, heart failure, concurrent polyvascular atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus, and different levels of expression of selected cardiovascular biomarkers, are discussed. "
4.	Diabetes Mellitus 10/23/2018 - "Letter by Donzelli et al Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)"." 10/23/2018 - "Letter by Koh Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)"." 10/01/2018 - "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)." 01/01/2021 - "In this second part of the review of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), the findings in relation to patients with stroke, the ACS phenotype, history of coronary artery bypass graft surgery, heart failure, concurrent polyvascular atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus, and different levels of expression of selected cardiovascular biomarkers, are discussed. "
5.	Hypercholesterolemia 11/01/2010 - "Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study)." 01/31/2012 - "In high cardiovascular risk subjects with hypercholesterolemia already treated with atorvastatin 20 mg but not at LDL-C < 2.59 mmol/L, switching to combination ezetimibe/simvastatin 10/40 mg provided significantly greater LDL-C lowering and greater achievement of LDL-C targets compared with doubling the atorvastatin dose to 40 mg. Both treatments were generally well-tolerated. " 11/15/2005 - "Ezetimibe/Simvastatin (vytorin) for hypercholesterolemia." 05/01/2006 - "Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study." 07/01/2005 - "Efficacy results from clinical trials with the co-administration of ezetimibe 10 mg with simvastatin or with the ezetimibe/simvastatin combination product (ezetimibe/simvastatin 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg) were compared with efficacy results from clinical trials of rosuvastatin 5 mg, 10 mg, 20 mg, and 40 mg in patients with primary hypercholesterolemia. "

Related Drugs and Biologics

1.	Ezetimibe (Zetia)
2.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
3.	Simvastatin (Zocor)
4.	oxidized low density lipoprotein
5.	LDL Cholesterol
6.	Atorvastatin (Lipitor)
7.	Cholesterol
8.	Lipoproteins (Lipoprotein)
9.	Apolipoproteins
10.	Proprotein Convertase 9

Related Therapies and Procedures

1.	Therapeutics
2.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
3.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
4.	Thrombectomy
5.	Secondary Prevention